earnings
confidence high
sentiment negative
materiality 0.85
Xtant Q2 revenue down 35% to $23M, net loss $9.4M, cuts FY guidance
Xtant Medical Holdings, Inc.
- Revenue $23.0M vs $35.4M YoY; net loss $9.4M vs income $3.6M.
- Adjusted EBITDA loss $2.7M vs +$6.9M; gross margin 57.9% vs 68.6%.
- FY2026 revenue guidance cut to $99-103M from $101-105M.
- Exclusive U.S. distribution deal with Dilon for HEMOBLAST Bellows; hired ~20-person sales team.
- Cash $9.9M, debt $23.0M, revolver availability $0.7M as of June 30, 2026.